These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 53531)

  • 1. Letter: L-dopa and 5-hydroxytryptophan therapy in phenylketonuria with normal phenylalanine-hydroxylase activity.
    Bartholomé K; Byrd DJ
    Lancet; 1975 Nov; 2(7943):1042-3. PubMed ID: 53531
    [No Abstract]   [Full Text] [Related]  

  • 2. Atypical phenylketonuria with normal phenylalanine hydroxylase and dihydropteridine reductase activity in vitro.
    Bartholomé K; Byrd DJ; Kaufman S; Milstien S
    Pediatrics; 1977 May; 59(5):757-61. PubMed ID: 300866
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neurotransmitter therapy and diet in malignant phenylketonuria.
    Ponzone A; Guardamagna O; Ferraris S; Biasetti S; Bracco G; Niederwieser A
    Eur J Pediatr; 1987 Jan; 146(1):93-4. PubMed ID: 2438135
    [No Abstract]   [Full Text] [Related]  

  • 4. Atypical phenylketonuria due to biopterin deficiency. Early treatment with tetrahydrobiopterin and neurotransmitter precursors, trials of monotherapy.
    Endres W; Niederwieser A; Curtius HC; Wang M; Ohrt B; Schaub J
    Helv Paediatr Acta; 1982; 37(5):489-98. PubMed ID: 6761317
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [A deficiency of dihydrobiopterin synthesis. The effects of L-dopa, 5HTP and BH4].
    Fujita N; Tanaka K; Nakajima T; Miyatake T; Ohwada M
    Rinsho Shinkeigaku; 1988 Apr; 28(4):376-81. PubMed ID: 3265083
    [No Abstract]   [Full Text] [Related]  

  • 6. 6-pyruvoyl-tetrahydropterin synthase deficiency with mild hyperphenylalaninemia.
    Demos MK; Waters PJ; Vallance HD; Lillquist Y; Makhseed N; Hyland K; Blau N; Connolly MB
    Ann Neurol; 2005 Jul; 58(1):164-7. PubMed ID: 15984017
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Malignant phenylketonuria due to defective synthesis of dihydrobiopterin.
    Cohen BE; Szeinberg A; Quint J; Normand M; Blonder J; Peled I
    Isr J Med Sci; 1985 Jun; 21(6):520-5. PubMed ID: 3874852
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monoaminergic effects of folinic acid, L-DOPA, and 5-hydroxytryptophan in dihydropteridine reductase deficiency.
    Goldstein DS; Hahn SH; Holmes C; Tifft C; Harvey-White J; Milstien S; Kaufman S
    J Neurochem; 1995 Jun; 64(6):2810-3. PubMed ID: 7760062
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Successful long term therapy of biopterin deficiency.
    Snyderman SE; Sansaricq C; Pulmones MT
    J Inherit Metab Dis; 1987; 10(3):260-6. PubMed ID: 3123784
    [TBL] [Abstract][Full Text] [Related]  

  • 10. l-5-Hydroxytryptophan in depression: the first substitution therapy in psychiatry? The treatment of 99 out-patients with 'therapy-resistant' depressions.
    van Hiele LJ
    Neuropsychobiology; 1980; 6(4):230-40. PubMed ID: 6967194
    [No Abstract]   [Full Text] [Related]  

  • 11. Biopterin synthesis defect. Treatment with L-dopa and 5-hydroxytryptophan compared with therapy with a tetrahydropterin.
    McInnes RR; Kaufman S; Warsh JJ; Van Loon GR; Milstien S; Kapatos G; Soldin S; Walsh P; MacGregor D; Hanley WB
    J Clin Invest; 1984 Feb; 73(2):458-69. PubMed ID: 6142058
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dihydropteridine reductase deficiency associated with severe neurologic disease and mild hyperphenylalaninemia.
    Brewster TG; Moskowitz MA; Kaufman S; Breslow JL; Milstien S; Abroms IF
    Pediatrics; 1979 Jan; 63(1):94-9. PubMed ID: 312482
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Malignant phenylketonuria caused by biopterin synthetase deficiency. Study of neuromediator catabolites in the cerebrospinal fluid during treatment].
    Malpuech G; Guyon A; Demeocq F; Piton A; Boespflug O; Vanlieferinghen P
    Arch Fr Pediatr; 1984 Jan; 41(1):5-8. PubMed ID: 6202269
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term therapy of myoclonus and other neurologic disorders with L-5-hydroxytryptophan and carbidopa.
    Van Woert MH; Rosenbaum D; Howieson J; Bowers MB
    N Engl J Med; 1977 Jan; 296(2):70-5. PubMed ID: 401457
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of a scleroderma-like illness during therapy with L-5-hydroxytryptophan and carbidopa.
    Sternberg EM; Van Woert MH; Young SN; Magnussen I; Baker H; Gauthier S; Osterland CK
    N Engl J Med; 1980 Oct; 303(14):782-7. PubMed ID: 6997735
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dihydropteridine reductase deficiency: levodopa's long-term effectiveness without dyskinesia.
    Sedel F; Ribeiro MJ; Remy P; Blau N; Saudubray JM; Agid Y
    Neurology; 2006 Dec; 67(12):2243-5. PubMed ID: 17190955
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Letter: Psychosis in patient on bromocriptine and levodopa with carbidopa.
    Lipper S
    Lancet; 1976 Sep; 2(7985):571-2. PubMed ID: 60643
    [No Abstract]   [Full Text] [Related]  

  • 18. [Combined treatment of Parkinsonism with L-dopa and peripheral dopa decarboxylase inhibitors--clinical course of 13 cases and levels of serum/dopa and dopamine].
    Mizuno Y; Yoshida M; Obayashi T; Ueki A
    Rinsho Shinkeigaku; 1976 Jul; 16(7):511-9. PubMed ID: 986921
    [No Abstract]   [Full Text] [Related]  

  • 19. What Is Not in the Name? Dopa-Responsive Dystonia May Respond to More Than L-Dopa.
    Friedman JR
    Pediatr Neurol; 2016 Jun; 59():76-80. PubMed ID: 27080360
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacologic maintenance of abstinence in patients with alcoholism: no efficacy of 5-hydroxytryptophan or levodopa.
    George DT; Lindquist T; Rawlings RR; Eckardt MJ; Moss H; Mathis C; Martin PR; Linnoila M
    Clin Pharmacol Ther; 1992 Nov; 52(5):553-60. PubMed ID: 1424429
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.